Drug updates and approvals: 2017 in review

In 2017, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: brodalumab (Siliq), dapagliflozin and saxagliptin (Qtern), dupilumab (Dupixent), oxymetazoline (Rhofade), safinamide (Xadago), and sarilumab (Kevzara).

Get Content & Permissions

Responding to child sexual abuse disclosure

In cases of child sexual abuse (CSA), NPs are faced with a variety of options dictated by community, agency, and individual resources. This article looks at victim-centered care from current guidelines and offers resources for clinical practice decision making when responding to CSA disclosure.

Get Content & Permissions
Powered by:

Quick Poll

​​

Women will spend one-third of their lives in and beyond menopause.
Women will spend one-third of their lives in and beyond menopause.
Women will spend one-third of their lives in and beyond menopause.
 Submit
 Clear
 Results